Efficacy and safety of Chinese herbal medicine versus Lopinavir-Ritonavir in adult patients with coronavirus disease 2019 : A non-randomized controlled trial

Copyright © 2020. Published by Elsevier GmbH..

BACKGROUND: Treatments for coronavirus disease 2019 (COVID-19) are limited by suboptimal efficacy.

METHODS: From January 30, 2020 to March 23, 2020, we conducted a non-randomised controlled trial, in which all adult patients with laboratory-confirmed COVID-19 were assigned to three groups non-randomly and given supportive treatments: Group A, Lopinavir-Ritonavir; Group B, Huashi Baidu Formula (a Chinese medicineformula made by the China Academy of Chinese Medical Sciences to treat COVID-19, which is now in the clinical trial period) and Lopinavir-Ritonavir; and Group C, Huashi Baidu Formula. The use of antibiotics, antiviruses, and corticosteroids was permitted in Group A and B. Traditional Chinese medicine injections were permitted in Group C. The primary outcomes were clinical remission time (interval from admission to the first time the patient tested negatively for novel coronavirus or an obvious improvement was observed from chest CT) and clinical remission rate (number of patients whose clinical time was within 16 days/total number of patients).

RESULTS: A total of 60 adult patients with COVID-19 were enrolled at sites in Wuhan, China, and the sample size of each group was 20. In Groups A, B and C, the clinical remission rates were 95.0%%(19/20), 100.0%%(20/20) and 100.0%%(20/20), respectively. Compared with Groups A and B, the clinical remission time of Group C was significantly shorter (5.9 days vs. 10.8 days, p < 0.05; 5.9 days vs. 9.7 days, p < 0.05). There was no significant difference among Groups A, B, and C in terms of the time taken to be released from quarantine. The clinical biochemical indicators and safety indexes showed no significant differences among the three groups.

CONCLUSIONS: Our findings suggest that Lopinavir-Ritonavir has some efficacy in the treatment of COVID-19, and the Huashi Baidu Formula might enhance this effect to an extent. In addition, superiority was displayed in the treatment of COVID-19 through a combination of the Huashi Baidu Formula and traditional Chinese medicine injection. In future, well-designed prospective double-blinded randomised control trials are required to confirm our findings.

Media Type:

Electronic Article

Year of Publication:

2021

Contained In:

Phytomedicine : international journal of phytotherapy and phytopharmacology - Vol. 81 (2021), p. 153367

Language:

English

Contributors:

Shi, Nannan
Guo, Lanping
Liu, Bin
Bian, Yongjun
Chen, Renbo
Chen, Suping
Chen, Yang
Chen, Yingying
Cong, Xiaodong
Dong, Guoju
Guo, Jing
Hu, Lijie
Jiang, Jianxin
Leng, Luxing
Li, Bin
Li, Dongxu
Li, Hao
Li, Jing
Li, Li
Liu, Jia
Lu, Cheng
Lv, Wenliang
Miao, Qing
Qi, Wensheng
Shi, Zhan
Shi, Jiaheng
Shi, Huaxin
Tian, Yaxin
Wang, Bing
Wang, Gang
Wang, Jian
Wang, Wei
Xian, Yongyue
Xie, Xiaolei
Xiong, Yibai
Xu, Chunyan
Xu, Ming
Yan, Bei
Yang, Jinliang
Zhang, Li
Zhou, Zhenqi
Zhu, Haoning
Huang, Luqi

Links:

Volltext

Keywords:

2494G1JF75
Adult
Aged
Aged, 80 and over
Antiviral Agents
COVID-19
Chinese herbal medicine
Coronavirus disease 2019
Drug Combinations
Drug Therapy, Combination
Drugs, Chinese Herbal
Female
Huashi baidu
Humans
Journal Article
Lopinavir
Lopinavir-Ritonavir
Lopinavir-ritonavir drug combination
Male
Medicine, Chinese Traditional
Middle Aged
Non-randomized controlled trial
O3J8G9O825
Patient Safety
Prospective Studies
Ritonavir
Thorax
Tomography, X-Ray Computed
Treatment Outcome

Notes:

Date Completed 14.01.2021

Date Revised 14.01.2021

published: Print-Electronic

Citation Status MEDLINE

Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Physical Description:

Online-Ressource

doi:

10.1016/j.phymed.2020.153367

PMID:

33260064

PPN (Catalogue-ID):

NLM319262413